Giselle L Saulnier Sholler (Giselle Saulnier Sholler, Giselle S Sholler)

Years Active: 2020-2023
Publications (10 Years): 3

This page only lists publications with an associated author ORCID identifier.

Publications

Don Eslin, Peter E Zage, Genevieve Bergendahl, Elizabeth Lewis, William Roberts, Jacqueline Kraveka, Deanna Mitchell, Michael S Isakoff, Jawhar Rawwas, Randal K Wada, Mark Fluchel, Valerie I Brown, Kevin Ginn, Timothy Higgins, Abhinav BeeravallyNagulapally, Karl Dykema, Gina Hanna, William Ferguson, Giselle L Saulnier Sholler
A phase II trial of nifurtimox combined with topotecan and cyclophosphamide for refractory or relapsed neuroblastoma and medulloblastoma. International journal of cancer (2023)
Izhar S Batth, Long Dao, Arun Satelli, Abhisek Mitra, Sofia Yi, Hyangsoon Noh, Heming Li, Zachary Brownlee, Shouhao Zhou, Jeffrey Bond, Jing Wang, Jonathan Gill, Giselle L Saulnier Sholler, Shulin Li
Cell surface vimentin-positive circulating tumor cell-based relapse prediction in a long-term longitudinal study of postremission neuroblastoma patients. International journal of cancer 147 (12) (2020)
Tyler Maser, Joseph Zagorski, Shannon Kelly, Anna Ostrander, Austin Goodyke, Abhinav Nagulapally, Jeffrey Bond, Yeonhee Park, Giselle L Saulnier Sholler
The MDM2 inhibitor CGM097 combined with the BET inhibitor OTX015 induces cell death and inhibits tumor growth in models of neuroblastoma. Cancer medicine 9 (21) (2020)

Giselle L Saulnier Sholler.css-eqlu8i{font-size:small;padding-left:4px;} (Giselle Saulnier Sholler, Giselle S Sholler)